Étiquette : ASH
-
Advanced BioDesign to Present Groundbreaking Research data on AML at the 67th ASH Annual Meeting
Lyon, France – December 5th, 2025 — Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, is proud to announce its participation at the American Society of Hematology (ASH) Annual Meeting 2025 with two significant scientific contributions. Oral Presentation Title: Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance…
Advanced BioDesign 